Amrutanjan Health Care Ltd
Amrutanjan Health Care Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹127Cr
- Net profit
- ₹14Cr
- Margin
- 13%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY24 Net Sales: - OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) - Comfy: ₹31.11 Cr, up 59.87% YoY (Q4 FY23: ₹19.46 Cr) - Beverages: ₹18.67 Cr, up 25.81% YoY (Q4 FY23: ₹14.84 Cr) - Ele Quarterly Financials (Q4 FY24 vs Q4 FY23): - Operating Profit (approximate from Operating Profit % on page 24): FY24 Operating Profit % is 10.89% vs 10.36% in FY23 (year-on-year increase of 0.53 ppt).
From Amrutanjan Health Care Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY24 Net Sales:
- OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr)
- Comfy: ₹31.11 Cr, up 59.87% YoY (Q4 FY23: ₹19.46 Cr)
- Beverages: ₹18.67 Cr, up 25.81% YoY (Q4 FY23: ₹14.84 Cr)
- Electro Plus: ₹17.56 Cr, up 37.29% YoY (Q4 FY23: ₹12.79 Cr)
- FY24 Net Sales:
- OTC: ₹380.39 Cr, up 10.22% YoY (FY23: ₹345.11 Cr)
- Comfy: ₹108.26 Cr, up 37.63% YoY (FY23: ₹78.66 Cr)
- Beverages: ₹39.98 Cr, up 23.17% YoY (FY23: ₹32.46 Cr)
- Electro Plus: ₹33.75 Cr, up 25.75% YoY (FY23: ₹26.84 Cr)
- Volume Growth:
- Head category volume growth: 3.9%
- Body category volume growth: 7%
- Back Pain Roll-on volume growth: 20.5%
- Outlook:
- Target revenue of ₹1000 Cr by FY28
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q3 FY24 | QoQ |
|---|---|---|---|
| Revenue | 127 | 117 | +8.5% |
| Operating profit (EBITDA) | 16 | 22 | -27.3% |
| Operating margin | 13% | 18% | -5 pp |
| Profit before tax | 20 | 24 | -16.7% |
| Net profit (PAT) | 14 | 17 | -17.6% |
| EPS (₹) | 4.72 | 6.04 | -21.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY24)
1,759 Cr, a 5% YoY increase from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Bharat Parenterals (Q4 FY24)
For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key concall takeaways from Bharat…
- Themis Medicare (Q4 FY24)
97.82 Cr, up 22.11% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Fermenta Biotech (Q4 FY24)
Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) . Key concall takeaways from Fermenta Biotech Ltd's Q4 FY24 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q4 FY24 results?
Q4 FY24 Net Sales: - OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) - Comfy: ₹31.11 Cr, up 59.87% YoY (Q4 FY23: ₹19.46 Cr) - Beverages: ₹18.67 Cr, up 25.81% YoY (Q4 FY23: ₹14.84 Cr) - Ele Quarterly Financials (Q4 FY24 vs Q4 FY23): - Operating Profit (approximate from Operating Profit % on page 24): FY24 Operating Profit % is 10.89% vs 10.36% in FY23 (year-on-year increase of 0.53 ppt).
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.